학술논문
Evaluation of BMS-986142, a reversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2, randomised, double-blind, dose-ranging, placebo-controlled, adaptive design study
Document Type
Article
Author
Source
In The Lancet Rheumatology May 2023 5(5):e263-e273
Subject
Language
ISSN
2665-9913